Naltrexone, an orally semisynthetic MOR antagonist, was demonstrated to be effective in suppressing pruritus in patients with CTCL [216, 248–250], and another MOR antagonist, naloxone, improved pruritus in a patient with MF [251]. The gene discussed is OPRM1; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.